M
Michael J. Hogan
Researcher at University of Pennsylvania
Publications - 15
Citations - 4132
Michael J. Hogan is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Immunization & Immune system. The author has an hindex of 10, co-authored 14 publications receiving 2128 citations. Previous affiliations of Michael J. Hogan include Hospital of the University of Pennsylvania & Children's Hospital of Philadelphia.
Papers
More filters
Journal ArticleDOI
mRNA vaccines — a new era in vaccinology
TL;DR: A detailed overview of mRNA vaccines is provided and future directions and challenges in advancing this promising vaccine platform to widespread therapeutic use are considered.
Journal ArticleDOI
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Norbert Pardi,Michael J. Hogan,Rebecca S. Pelc,Hiromi Muramatsu,Hanne Andersen,Christina R. DeMaso,Kimberly A. Dowd,Laura L. Sutherland,Richard M. Scearce,Robert Parks,Wendeline Wagner,Alex Granados,Jack Greenhouse,Michelle Walker,Elinor Willis,Jae-Sung Yu,Charles E. McGee,Gregory D. Sempowski,Barbara L. Mui,Ying K. Tam,Yan Jang Huang,Dana L. Vanlandingham,Veronica M. Holmes,Harikrishnan Balachandran,Sujata Sahu,Michelle A. Lifton,Stephen Higgs,Scott E. Hensley,Thomas D. Madden,Michael J. Hope,Katalin Karikó,Sampa Santra,Barney S. Graham,Mark G. Lewis,Theodore C. Pierson,Barton F. Haynes,Drew Weissman +36 more
TL;DR: It is demonstrated that a single low-dose intradermal immunization with nucleoside-modified mRNA–LNP elicits rapid and durable protective immunity and therefore represents a new and promising vaccine candidate for the global fight against ZIKV.
Journal ArticleDOI
Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses.
Norbert Pardi,Michael J. Hogan,Martin S. Naradikian,Kaela Parkhouse,Derek W. Cain,Letitia D. Jones,M. Anthony Moody,Hans P. Verkerke,Arpita Myles,Elinor Willis,Celia C. LaBranche,David C. Montefiori,Jenna L. Lobby,Kevin O. Saunders,Hua-Xin Liao,Bette T. Korber,Laura L. Sutherland,Richard M. Scearce,Peter T. Hraber,István Tombácz,Hiromi Muramatsu,Houping Ni,Daniel A. Balikov,Charles Q. Li,Barbara L. Mui,Ying K. Tam,Florian Krammer,Katalin Karikó,Patricia Polacino,Laurence C. Eisenlohr,Thomas D. Madden,Michael J. Hope,Mark G. Lewis,Kelly K. Lee,Shiu Lok Hu,Scott E. Hensley,Michael P. Cancro,Barton F. Haynes,Drew Weissman +38 more
TL;DR: A recently developed vaccine platform, nucleoside-modified, purified mRNA encapsulated in lipid nanoparticles (mRNA-LNPs), that induces high levels of Tfh and GC B cells that are associated with long-lived and high-affinity neutralizing antibodies and durable protection.
Journal ArticleDOI
SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation.
Katlyn Lederer,Diana Castaño,Diana Castaño,Daniela Gómez Atria,Thomas H. Oguin,Sidney Wang,Tomaz B. Manzoni,Hiromi Muramatsu,Michael J. Hogan,Fatima Amanat,Patrick Cherubin,Kendall A. Lundgreen,Ying K. Tam,Steven H.Y. Fan,Laurence C. Eisenlohr,Laurence C. Eisenlohr,Ivan Maillard,Drew Weissman,Paul Bates,Florian Krammer,Gregory D. Sempowski,Norbert Pardi,Michela Locci +22 more
TL;DR: Overall, this study identifies SARS-CoV-2 mRNA vaccines as strong candidates for promoting robust GC-derived immune responses and directly compared two vaccine platforms −mRNA vaccines and a recombinant protein formulated with an MF59-like adjuvant− for their ability to quantitatively and qualitatively shape Sars-Cov-2-specific primary GC responses over time.
Journal ArticleDOI
Recent advances in mRNA vaccine technology
TL;DR: This review summarizes the most important developments in mRNA vaccines from the past few years and discusses the challenges and future directions for the field.